Experimental Hematology & Oncology

Table 2 Comparisons of progression-free and overall survival

From: Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Comparison	Before matching			After matching
Comparison	HR	95% CI	P-Value	HR	95% CI	P-Value
Progression-free survival
Everolimus vs. Placebo	0.38	0.29-0.49	<0.001	0.35	0.24-0.52	<0.001
Sunitinib vs. Placebo	0.42	0.26-0.66	<0.001	0.42	0.26-0.66	<0.001
Everolimus vs. Sunitinib^a	0.90	0.53-1.53	0.695	0.84	0.46-1.53	0.578
Overall survival
Everolimus vs. Placebo in A6181111	0.53	0.35-0.78	0.002	0.61	0.38-0.98	0.042
Everolimus vs. Sunitinib	0.69	0.46-1.05	0.087	0.81	0.49-1.31	0.383

Notes:
^aComparison based on the HR for everolimus vs. placebo divided by the HR for sunitinib vs. placebo.

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com